Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

SynAct Pharma

20.55 SEK

+0.49 %

Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.49 %
-10.26 %
+8.04 %
+9.78 %
+129.22 %
+82.55 %
-67.60 %
-41.31 %
+345.81 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
1.1B SEK
Turnover
859.91K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18/2
2026

Annual report '25

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release11/27/2025, 10:15 AM

Kommuniké från extra bolagsstämma i SynAct Pharma AB

SynAct Pharma
Regulatory press release11/27/2025, 10:15 AM

Report from the Extraordinary General Meeting of SynAct Pharma AB

SynAct Pharma
Press release11/19/2025, 7:34 AM

BioStock: Video från SynAct Pharma presentation vid BioStock Life Science Summit 2025

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/19/2025, 7:34 AM

BioStock: Video from SynAct Pharma's presentation at BioStock Life Science Summit 2025

SynAct Pharma
Press release11/19/2025, 6:30 AM

SynAct Pharma deltar på Redeyes event Autoimmune and Inflammatory Diseases den 19 november

SynAct Pharma
Press release11/19/2025, 6:30 AM

SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th

SynAct Pharma
Third party research11/6/2025, 9:37 AM

Synact Pharma: Differentiated inflammation resolution approach - Edison

SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to have direct effects on the immune system. The main ...

SynAct Pharma
Press release11/3/2025, 7:00 AM

190 patienter randomiserade i SynAct Pharmas fas 2b-studie ADVANCE – rekrytering förväntas slutföras vid årsskiftet

SynAct Pharma
Press release11/3/2025, 7:00 AM

Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion

SynAct Pharma
Press release10/31/2025, 10:44 AM

Redeye: SynAct (Q3 Update) - ADVANCE Approaching Full Recruitment

SynAct Pharma
Press release10/31/2025, 10:43 AM

BioStock: SynAct stärker pipeline och förlänger finansieringen till 2027

SynAct Pharma
Press release10/31/2025, 10:43 AM

BioStock: SynAct advances pipeline and extends runway to 2027

SynAct Pharma
Press release10/31/2025, 7:00 AM

SynAct Pharma deltar på partner- och investerarkonferensen Bio-Europe® 2025

SynAct Pharma
Press release10/31/2025, 7:00 AM

SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025

SynAct Pharma
Regulatory press release10/30/2025, 6:30 AM

SynAct Pharma publicerar delårsrapport Q3 2025

SynAct Pharma
Regulatory press release10/30/2025, 6:30 AM

SynAct Pharma publishes Q3 2025 interim results

SynAct Pharma
Regulatory press release10/29/2025, 5:30 PM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I SYNACT PHARMA AB (PUBL)

SynAct Pharma
Regulatory press release10/29/2025, 5:30 PM

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF SYNACT PHARMA AB

SynAct Pharma
Press release10/28/2025, 9:50 AM

Edison Investment Research inleder bevakning av SynAct Pharma

SynAct Pharma
Press release10/28/2025, 9:50 AM

Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma

SynAct Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.